Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials

C Glazener,1* C Boachie,1 B Buckley,2 C Cochran,1 G Dorey,3 A Grant,4 S Hagen,5 M Kilonzo,6 A McDonald,1 G McPherson,1 K Moore,7 J N’Dow,8 J Norrie,9 C Ramsay1 and L Vale1

1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Bladder and Bowel Foundation, Kettering, UK
3University of the West of England, Bristol, UK
4College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
5Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, UK
6Health Economics Research Unit, University of Aberdeen, Aberdeen, UK
7University of Alberta, Edmonton, AB, Canada
8Academic Urology Unit, University of Aberdeen, Aberdeen, UK
9Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

*Corresponding author

Executive summary

Health Technology Assessment 2011; Vol. 15: No. 24
DOI: 10.3310/hta15240

Health Technology Assessment
NIHR HTA programme
www.hta.ac.uk
Executive summary

Background

Successive Cochrane reviews have shown that, although conservative treatment based on pelvic floor muscle training (PFMT) may be offered to men with urinary incontinence after prostate surgery, there is insufficient evidence to evaluate its effectiveness and cost-effectiveness. Men After Prostate Surgery (MAPS) was a multicentre, UK, randomised controlled trial (RCT), the aim of which was to supply that evidence for men undergoing radical prostatectomy or transurethral resection of the prostate (TURP).

Radical prostatectomy is carried out for men suffering from early prostate cancer. The operation is usually carried out through an open incision in the abdomen, which may damage the urinary bladder sphincter, or its nerve supply, and other pelvic structures. Urinary incontinence occurs in around 90% of men initially but the long-term prognosis varies from 2% to 60%, depending on how incontinence is measured and time after surgery. TURP is carried out using an endoscope through the urethra: the aim is to remove enlarged prostate tissue from the lumen of the urethra. Damage to the distal urinary bladder sphincter or its nerve supply is less common than with radical surgery, and fewer men remain incontinent (an estimated 11% of men wear pads 3 months after surgery).

The two types of surgery were considered in two parallel but separate trials because the rates of incontinence and the chance of regaining continence were expected to differ between the two clinical populations.

Objectives

The following question was addressed, primarily in terms of regaining urinary continence at 12 months after recruitments for both types of surgery: what are the clinical effectiveness and cost-effectiveness of active conservative treatment delivered by a specialist continence physiotherapist or a specialist continence nurse compared with standard management?

The hypothesis tested in each group of men was that active conservative management would result in a difference of 15% between the groups in the proportion of incontinent men at 1 year after recruitment.

Methods

Men having prostate surgery were identified in 34 centres across the UK. Men were invited to receive a screening questionnaire after their operation. Those who reported at screening that they were incontinent were invited to enrol in MAPS.

Inclusion criteria were full informed consent; ability to comply with intervention; and urinary incontinence at 6 weeks after prostate surgery. Incontinence was defined as a ‘positive’ response to either of two questions in the screening questionnaire: ‘how often do you leak urine?’ and ‘how much urine do you leak?’.
Exclusion criteria were formal referral for physiotherapy or teaching of PFMT related to prostate surgery; radiotherapy planned or given during the first 3 months after surgery for men with prostate cancer; resection of prostate as palliation for outflow obstruction in advanced prostate cancer (known as ‘channel TURP’); and inability to complete study questionnaires.

Men completed a questionnaire at 6 weeks after surgery and signed a consent form. Baseline information included sociodemographic and clinical characteristics including type of operation. Eligible men were randomised to attending four sessions with a therapist over a period of 3 months (intervention group). The therapists were either specialist continence physiotherapists or specialist continence or urology nurses. All therapists were provided with standardised training in the management of male urinary incontinence and erectile dysfunction. The control group received standard management. Both groups received a lifestyle advice leaflet.

Randomisation was by remote computer allocation using the randomisation service of the Centre for Healthcare Randomised Trials (CHaRT, Health Services Research Unit, University of Aberdeen). Allocation was stratified by type of operation (radical prostatectomy or TURP), and minimised using centre, age and pre-existing urinary incontinence. The process was independent of all clinical collaborators.

The primary clinical effectiveness outcome was urinary incontinence at 12 months after randomisation, and the primary cost-effectiveness outcome was incremental cost per QALY. Outcome data were collected by postal questionnaires at 3, 6, 9 and 12 months. At each time point, men also completed a urinary diary for 3 days. Data collected included: urinary outcomes (presence, frequency and severity of incontinence, effect of incontinence on quality of life, use of pads and catheters, type of incontinence, urinary frequency and nocturia); bowel outcomes (faecal incontinence, constipation, bowel urgency); sexual function (erectile function, ejaculation, change in sexual function); quality of life (EQ-5D and SF-12); use of health services (contact with community, hospital and private staff, use of alternative treatments such as pads, catheters, surgery, drugs or mechanical devices, and their costs); participants’ costs (self-purchased health care, costs of accessing health care, cost of time away from usual activities); QALY’s derived from responses to the EQ-5D and SF-12; and effect of the intervention in changing health-related behaviour and practice of PFMT and bladder training or urge suppression.

Results

We approached 1158 men having a radical prostatectomy and 5986 having TURP in 34 centres. The response rate for the screening questionnaire was 95% (742/780) of the eligible men in the radical prostatectomy group and 91% (2590/2838) in the TURP group.

Amongst the radical prostatectomy group, of 472 eligible men who returned a questionnaire after surgery, 411 entered the radical prostatectomy RCT: 205 in the intervention group and 206 in the control group. Follow-up rates were high (95% of all men in each arm, 97% and 98% respectively after accounting for withdrawals and deaths).

Ninety-two per cent of the men allocated to the intervention group attended at least one therapy visit. Men in the intervention group were more likely to be carrying out any PFMT at 12 months (67%) than those in the control group (50%, adjusted risk ratio (RR) 1.30, 95% confidence interval (CI) 1.09 to 1.53).

Among the men who had a radical prostatectomy, the difference in urinary incontinence rates at 12 months between the intervention and control groups (148/196, 75.5%, vs 151/195, 77.4%)
was not statistically significant: the absolute risk difference for the unadjusted intention-to-treat analysis was −1.9% (95% CI −10% to 6%), which ruled out the prespecified target difference of 15%. Adjusting for minimisation factors or performing a ‘treatment received’ analysis did not change these results.

NHS costs were higher in the intervention group (£181, 95% CI £107 to £255), but costs to the NHS and the participant were on average lower (−£588, 95% CI −£1330 to £153). On average, QALYs were virtually identical in both the intervention and the control groups (−0.002, 95% CI −0.027 to 0.023). When the perspective was the NHS there was only a 20% chance that PFMT would be cost-effective. However, from a societal perspective, there was an 80% chance that it would be cost-effective. The findings from the societal perspective were driven by a trend towards more time away from usual activities in the control group. These data are counter-intuitive when considered alongside the rest of the trial data and so should be treated cautiously.

Amongst those who had TURP, of 512 eligible men who returned a questionnaire at 6 weeks after surgery, 442 entered the TURP RCT: 220 in the intervention group and 222 in the control group. Follow-up rates were high (88% and 92% respectively of all men, 97% in both arms after accounting for withdrawals and deaths).

Over 85% of the men allocated to the intervention group attended at least one therapy visit. Men in the intervention group were more likely to be carrying out any PFMT at 12 months after randomisation (65%) than those in the control group (20%, adjusted RR 3.20, 95% CI 2.37 to 4.32).

Following a TURP, the difference between the intervention and control groups in the proportion of men who had urinary incontinence at 12 months (126/194, 64.9% vs 125/203, 61.5%) was not statistically significantly different: the absolute risk difference for the unadjusted intention-to-treat analysis was 3.4% (95% CI −6% to 13%), which rules out the prespecified target difference of 15%. Adjusting for minimisation factors or performing a ‘treatment received’ analysis did not change these results.

The differences in NHS costs (£209, 95% CI £147 to £271) and NHS and participant costs (£420, 95% CI £54 to £785) were higher in the intervention group. On average, QALYs were virtually identical in the intervention and control groups (−0.00003, 95% CI −0.026 to 0.026). From both a societal and an NHS perspective there was little chance that physical therapy would be considered cost-effective.

**Conclusions**

The provision of one-to-one conservative physical therapy for men with urinary incontinence after prostate surgery is unlikely to be effective or cost-effective compared with standard care (which includes the provision of information about conducting PFMT).

**Implications for research**

- Physical therapy of the type used in this trial is not worthwhile, but the continuing burden of incontinence suggests that research into other treatments is worthwhile, for example research on the value of surgery in controlling symptoms. Specifically, an RCT comparing different surgical options for men with severe persistent urinary incontinence is needed.
MAPS has not tested whether the provision of any PFMT advice is an effective and efficient way of reducing incontinence. Further research into the effectiveness of any other method of delivery of PFMT would be worthwhile.

Of the men in the radical prostatectomy trial, 80% still had erectile dysfunction at the 12-month follow-up, and over 60% had tried various treatments. As PFMT was of no value to these men, research into effective and efficient treatments for this condition would be worthwhile. Such a study should also include a wider population of men following radical surgery and not just those with urinary incontinence.

The MAPS data set can be used to improve the quality of further research and to improve other aspects of management. Specifically, MAPS data can be used to further validate the outcome measures for use in future research and clinical settings. The further analysis of the epidemiological data will inform the debate about different methods of prostatectomy and provide prognostic information for counselling men.

**Trial registration**

This trial is registered as ISRCTN87696430.

**Funding**

The National Institute for Health Research Health Technology Assessment programme.

**Publication**

The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

---

**Criteria for inclusion in the HTA journal series**

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors. Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 03/14/03. The contractual start date was in December 2004. The draft report began editorial review in March 2010 and was accepted for publication in August 2010. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

---

**Editor-in-Chief:** Professor Tom Walley CBE

**Series Editors:** Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Tom Marshall, Professor John Powell, Dr Rob Riemsma and Professor Ken Stein

**Associate Editor:** Dr Peter Davidson

**Editorial Contact:** edit@southampton.ac.uk

**ISSN 1366-5278 (Print)**

**ISSN 2046-4924 (Online)**

**ISSN 2046-4932 (DVD)**

© Queen’s Printer and Controller of HMSO 2011. This work was produced by Glazener et al. under the terms of a commissioning contract issued by the Secretary of State for Health.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org/).

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.

Printed on acid-free paper in the UK by the Charlesworth Group.